Clinical Trials Logo

Clinical Trial Summary

This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of Clostridium difficile infection (C diff).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03973697
Study type Interventional
Source University of Pennsylvania
Contact
Status Terminated
Phase Phase 2
Start date January 13, 2020
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT05201079 - Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin Phase 3
Terminated NCT01226992 - Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin Phase 2/Phase 3
Not yet recruiting NCT04960306 - Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT03462459 - Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05826418 - Dietary Optimization of Microbiome Recovery Following Fecal Microbiota Transplantation N/A
Completed NCT03497806 - Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection Phase 2
Suspended NCT01202630 - BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection Phase 3
Completed NCT03353506 - Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection Phase 2
Completed NCT01925417 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea Phase 2
Available NCT03786900 - Fecal Microbiota Transplantation (FMT): PRIM-DJ2727